liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Analyses of data of patients with Thrombotic Microangiopathy in the WAA registry
Umeå University.
Linköping University, Department of Clinical and Experimental Medicine. Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Centre for Diagnostics, Department of Clinical Immunology and Transfusion Medicine.
University of Uppsala Hospital.
University Hospital, Örebro.
Show others and affiliations
2011 (English)In: Transfusion and apheresis science, ISSN 1473-0502, E-ISSN 1878-1683, Vol. 45, no 2, 125-131 p.Article in journal (Refereed) Published
Abstract [en]

Thrombotic Microangiopathy (TMA) is a histopathological feature of various diseases including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. less thanbrgreater than less thanbrgreater thanThe aim of this study was to investigate the outcome and prognostic variables of TMA-patients. less thanbrgreater than less thanbrgreater thanMaterials and methods: Data were consecutively retrieved from the WAA-apheresis registry ( during 2003-2009. Included were all 120 patients (1237 procedures) who suffered from various forms of TMA, as registered by the ICD-10 code M31.1. Besides registry data, more extensive information was retrieved from the latest 64 patients. Adverse events of the TMA patients were compared to those of the other patients in the registry. less thanbrgreater than less thanbrgreater thanResults: The mean age was 46 years (range 11-85 years, 57% women). In 72% therapeutic apheresis was due to an acute indication while a long-term indication was present in 28%. Plasma exchange was performed by centrifugation and filtration technique (95% and 4%, respectively), and immunoadsorption in 1% of the patients. Only fresh frozen plasma was used as replacement fluid in 69% of procedures. Adverse events were more frequent than in the general apheresis population (10% versus 5%, RR 1.9, CI 1.6-2.3). No death occurred due to apheresis treatment. Three percent of the procedures were interrupted. Bronchospasm and/or anaphylactic shock were present in two patients and one patient suffered from TRALI. At admission 26% were bedridden and needed to be fed. The risk of dying during the treatment period was significantly higher if the patient also suffered from a compromising disease, such as cancer. There was an inverse correlation between the ADAMTS13 level and the antibody titer (r = -0.47, p = 0.034). less thanbrgreater than less thanbrgreater thanConclusions: Patients with TMA have an increased risk for moderate and severe AE compared to the general apheresis population. Many patients were severely ill at admission. The prognosis is worse if the patient also has a severe chronic disease. Even slightly increased ADAMTS13-antibody titers seem to have a negative impact on the ADAMTS13 levels. (C) 2011 Elsevier Ltd. All rights reserved.

Place, publisher, year, edition, pages
Elsevier , 2011. Vol. 45, no 2, 125-131 p.
Keyword [en]
Thrombotic Microangiopathy, Hemolytic uremic syndrome, ADAMTS13, Prognosis, TMA, TTP, HUS
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-72267DOI: 10.1016/j.transci.2011.07.001ISI: 000296406200004OAI: diva2:458798
Available from: 2011-11-24 Created: 2011-11-24 Last updated: 2011-11-24

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Berlin, Gösta
By organisation
Department of Clinical and Experimental MedicineFaculty of Health SciencesDepartment of Clinical Immunology and Transfusion Medicine
In the same journal
Transfusion and apheresis science
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 29 hits
ReferencesLink to record
Permanent link

Direct link